• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

FDA Approves First-Ever Standalone Therapy For Treatment-Resistant Depression

January 23, 2025 by Deborah Bloomfield

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved standalone treatment for this condition.

ADVERTISEMENT GO AD FREE

MDD is one of the most common mental health conditions in the US, affecting an estimated 21 million adults. Of those, around a third experience a treatment-resistant form of the condition; this means that their symptoms haven’t significantly alleviated after receiving standard treatments, such as at least two antidepressants and psychotherapy.

While there are existing avenues for such cases, including transcranial magnetic stimulation, researchers have also been exploring the possibility of using alternative antidepressant medications – that’s where the newly-approved nasal spray comes in.

Called SPRAVATO®, the nasal spray contains esketamine, a drug that is the chemical mirror-image (enantiomer) of the anesthetic drug ketamine. It had previously been FDA-approved back in 2019 – with some controversy, given the addictive nature of ketamine – for use with oral antidepressants.

Now, according to its manufacturer Johnson & Johnson, fresh clinical trial data has shown that the spray is effective on its own; at week 4 of the study, 22.5 percent of the patients taking SPRAVATO® had achieved remission from their treatment-resistant MDD, compared to 7.6 percent of the placebo group.

Like other antidepressants, the exact mechanism by which esketamine works to reduce depressive symptoms is unknown. However, esketamine increases levels of glutamate, an excitatory neurotransmitter.

Given the potential for abuse, there’s also some controversy over the use of esketamine as a treatment for depression. However, its approval doesn’t mean that it’ll be handed out with reckless abandon – the spray will only be available through a restricted program and can only be administered in a healthcare setting.

ADVERTISEMENT GO AD FREE

Patients will then have to be monitored by a healthcare provider for at least two hours for serious side effects – despite its apparent effectiveness, esketamine can still have side effects. According to Johns Hopkins Medicine, these can range from nausea and a headache all the way through to dissociation and hallucinations, though they tend to peak at around 40 minutes after the drug is administered and decrease thereafter.

Nonetheless, those behind the development of the spray are hopeful that its approval will make a difference to people with MDD.

“Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants or cannot tolerate them. For too long, healthcare providers have had few options to offer patients much-needed symptom improvement,” said Dr Bill Martin, Global Therapeutic Area Head, Neuroscience, Johnson & Johnson Innovative Medicine, in a statement.

Now, Martin continued, “patients may experience improvements in depressive symptoms as early as 24 hours and at 28 days – without the need for daily oral antidepressants.”

ADVERTISEMENT GO AD FREE

If you or someone you know is struggling, help and support are available in the US via the 988 Suicide & Crisis Lifeline which can be contacted by dialing 988. In the UK and Ireland, the Samaritans can be contacted on 116 123. International helplines can be found at SuicideStop.com.   

Deborah Bloomfield
Deborah Bloomfield

Related posts:

  1. China develops machines that can track data sent abroad by cars
  2. Russia arrests top cybersecurity executive in treason case
  3. Is LK-99 A Superconductor Or Not? What To Know About Recent Superconductor Claims
  4. Incredibly Rare Footage Of Bigfin Squid 3,300 Meters Deep In The Pacific

Source Link: FDA Approves First-Ever Standalone Therapy For Treatment-Resistant Depression

Filed Under: News

Primary Sidebar

  • 2024’s Great American Eclipse Made Some Birds Behave In Surprising Ways, But Not All Were Fooled
  • “Carter Catastrophe”: The Math Equation That Predicts The End Of Humanity
  • Why Is There No Nobel Prize For Mathematics?
  • These Are The Only Animals Known To Incubate Eggs In Their Stomachs And Give “Birth” Out Their Mouths
  • Constipated? This One Fruit Could Help, Says First-Ever Evidence-Led Diet Guidance
  • NGC 2775: This Galaxy Breaks The Rules Of “Galactic Evolution” And Baffles Astronomers
  • Meet The “Four-Eyed” Hirola, The World’s Most Endangered Antelope With Fewer Than 500 Left
  • The Bizarre 1997 Experiment That Made A Frog Levitate
  • There’s A Very Good Reason Why October 1582 On Your Phone Is Missing 10 Days
  • Skynet-1A: Military Spacecraft Launched 56 Years Ago Has Been Moved By Persons Unknown
  • There’s A Simple Solution To Helping Avoid Erectile Dysfunction (But You’re Not Going To Like It)
  • Interstellar Object 3I/ATLAS May Be 10 Billion Years Old, This Rare Spider Is Half-Female, Half-Male Split Down The Middle, And Much More This Week
  • Why Do Trains Not Have Seatbelts? It’s Probably Not What You Think
  • World’s Driest Hot Desert Just Burst Into A Rare And Fleeting Desert Bloom
  • Theoretical Dark Matter Infernos Could Melt The Earth’s Core, Turning It Liquid
  • North America’s Largest Mammal Once Numbered 60 Million – Then Humans Nearly Drove It To Extinction
  • North America’s Largest Ever Land Animal Was A 21-Meter-Long Titan
  • A Two-Headed Fossil, 50/50 Spider, And World-First Butt Drag
  • Interstellar Comet 3I/ATLAS Is Losing Buckets Of Water Every Second – And It’s Got Cyanide
  • “A Historic Shift”: Renewables Generated More Power Than Coal Globally For First Time
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version